— Know what they know.
Not Investment Advice
Also trades as: PHO.OL (OSL) · $vol 0M · 0IMT.L (LSE) · $vol 0M

PHCUF OTC

Photocure ASA
1W: +0.0% 1M: -6.0% 3M: -8.6% YTD: -19.3% 1Y: -3.8% 3Y: -51.0% 5Y: -21.0%
$5.65
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Strong Sell · Power 37 · $150.3M mcap · 26M float · 0.0002% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$150.3M
52W Range5.58-7.39
Volume100
Avg Volume64
Beta0.35
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODaniel Schneider
Employees101
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2013-09-24
Hoffsveien 4
Oslo, PS 0275
NO
47 22 06 22 10
About Photocure ASA

Photocure ASA, a specialty pharmaceutical company established in Oslo, Norway in 1993, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing, distribution, and commercialization. The company's reach extends across the Nordic countries, major European markets like Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, as well as the United States. Key offerings include Hexvix/Cysview, which is used for the identification and ongoing care of bladder cancer. Additionally, Photocure is currently developing Cevira, a treatment designed for human papillomavirus (HPV) infections and precancerous lesions of the cervix. Its products are supplied to pharmaceutical wholesalers, pharmacies, and hospitals primarily through strategic licensing partnerships.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms